CHT [CHUNGHWA TELECOM CO] 6-K: (Original Filing)
[Description 99.01 Announcement on 2020/04/17: To announce the differences between the year of 2019 financial statements under Taiwan-IFRSs and IFRSs 2 Chunghwa Telecom Co., Ltd. Shui-Yi Kuo]
CHT [CHUNGHWA TELECOM CO] 6-K: Description 99.01 Announcement on 2020/04/17: To announce the
[Description 99.01 Announcement on 2020/04/17: To announce the differences between the year of 2019 financial statements under Taiwan-IFRSs and IFRSs 2 Chunghwa Telecom Co., Ltd. Shui-Yi Kuo]
CYOU [Changyou.com] SC 13E3/A: (Original Filing)
[This statement is filed in connection with (check the appropriate box): a. ☐ 13e-3(c) The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19 BEIJING --(BUSINESS WIRE)-- April 17, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Compa]
CYOU [Changyou.com] SC 13E3/A: This statement is filed in connection with (check
[This statement is filed in connection with (check the appropriate box): a. ☐ 13e-3(c) The filing of solicitation materials or an information statement subject to Regulation 14A, Regulation 14C or Rule]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Announces Commencement of Phase I Human Clinical
[Sinovac Announces Commencement of Phase I Human Clinical Trial for Vaccine Candidate Against COVID-19 BEIJING --(BUSINESS WIRE)-- April 17, 2020-- Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Compa]
